View in EDS

Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma.

Saved in:
Bibliographic Details
Title: Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma.
Authors: O'Reilly EM; Memorial Sloan Kettering Cancer Center, New York, New York, USA rhv@upenn.edu oreillye@mskcc.org., Cabanski CR; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Lyman JP; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Wainberg ZA; University of California Los Angeles, Los Angeles, California, USA., Fisher GA; Department of Medicine, Stanford University School of Medicine, Stanford, California, USA., Wolff RA; MD Anderson Gastrointestinal Cancer Center, Houston, Texas, USA., Ko AH; Medicine (Division of Hematology/Oncology), University of California San Francisco, San Francisco, California, USA., O'Hara MH; Medicine, Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Spencer CN; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Yu JX; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Da Silva DM; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Padrón LJ; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Arnott J; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Fairchild J; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Moore JS; Abramson Cancer Center, Philadelphia, Pennsylvania, USA., Peng B; University of Pennsylvania, Philadelphia, Pennsylvania, USA., Hoos WA; 1440 Foundation, Scotts Valley, California, USA., O'Donnell-Tormey J; Cancer Research Institute, New York, New York, USA., Boffo S; Bristol Myers Squibb, Princeton, New Jersey, USA., Dugan U; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Kimmelman AC; NYU Langone Health Perlmutter Cancer Center, New York, New York, USA., Amaravadi RK; University of Pennsylvania, Philadelphia, Pennsylvania, USA., Vonderheide RH; Abramson Cancer Center, Philadelphia, Pennsylvania, USA rhv@upenn.edu oreillye@mskcc.org.; Parker Institute for Cancer Immunotherapy, Philadelphia, Pennsylvania, USA.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Jan 30; Vol. 14 (1). Date of Electronic Publication: 2026 Jan 30.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41617393
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22O'Reilly+EM%22">O'Reilly EM</searchLink>; Memorial Sloan Kettering Cancer Center, New York, New York, USA rhv@upenn.edu oreillye@mskcc.org.<br /><searchLink fieldCode="AU" term="%22Cabanski+CR%22">Cabanski CR</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Lyman+JP%22">Lyman JP</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Wainberg+ZA%22">Wainberg ZA</searchLink>; University of California Los Angeles, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Fisher+GA%22">Fisher GA</searchLink>; Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.<br /><searchLink fieldCode="AU" term="%22Wolff+RA%22">Wolff RA</searchLink>; MD Anderson Gastrointestinal Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Ko+AH%22">Ko AH</searchLink>; Medicine (Division of Hematology/Oncology), University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22O'Hara+MH%22">O'Hara MH</searchLink>; Medicine, Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Spencer+CN%22">Spencer CN</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Yu+JX%22">Yu JX</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Da+Silva+DM%22">Da Silva DM</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Padrón+LJ%22">Padrón LJ</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Arnott+J%22">Arnott J</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Fairchild+J%22">Fairchild J</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Moore+JS%22">Moore JS</searchLink>; Abramson Cancer Center, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Peng+B%22">Peng B</searchLink>; University of Pennsylvania, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Hoos+WA%22">Hoos WA</searchLink>; 1440 Foundation, Scotts Valley, California, USA.<br /><searchLink fieldCode="AU" term="%22O'Donnell-Tormey+J%22">O'Donnell-Tormey J</searchLink>; Cancer Research Institute, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Boffo+S%22">Boffo S</searchLink>; Bristol Myers Squibb, Princeton, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Dugan+U%22">Dugan U</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Kimmelman+AC%22">Kimmelman AC</searchLink>; NYU Langone Health Perlmutter Cancer Center, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Amaravadi+RK%22">Amaravadi RK</searchLink>; University of Pennsylvania, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Vonderheide+RH%22">Vonderheide RH</searchLink>; Abramson Cancer Center, Philadelphia, Pennsylvania, USA rhv@upenn.edu oreillye@mskcc.org.; Parker Institute for Cancer Immunotherapy, Philadelphia, Pennsylvania, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2026 Jan 30; Vol. 14 (1). <i>Date of Electronic Publication: </i>2026 Jan 30.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41617393
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1136/jitc-2025-012864
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: O'Reilly EM
      – PersonEntity:
          Name:
            NameFull: Cabanski CR
      – PersonEntity:
          Name:
            NameFull: Lyman JP
      – PersonEntity:
          Name:
            NameFull: Wainberg ZA
      – PersonEntity:
          Name:
            NameFull: Fisher GA
      – PersonEntity:
          Name:
            NameFull: Wolff RA
      – PersonEntity:
          Name:
            NameFull: Ko AH
      – PersonEntity:
          Name:
            NameFull: O'Hara MH
      – PersonEntity:
          Name:
            NameFull: Spencer CN
      – PersonEntity:
          Name:
            NameFull: Yu JX
      – PersonEntity:
          Name:
            NameFull: Da Silva DM
      – PersonEntity:
          Name:
            NameFull: Padrón LJ
      – PersonEntity:
          Name:
            NameFull: Arnott J
      – PersonEntity:
          Name:
            NameFull: Fairchild J
      – PersonEntity:
          Name:
            NameFull: Moore JS
      – PersonEntity:
          Name:
            NameFull: Peng B
      – PersonEntity:
          Name:
            NameFull: Hoos WA
      – PersonEntity:
          Name:
            NameFull: O'Donnell-Tormey J
      – PersonEntity:
          Name:
            NameFull: Boffo S
      – PersonEntity:
          Name:
            NameFull: Dugan U
      – PersonEntity:
          Name:
            NameFull: Kimmelman AC
      – PersonEntity:
          Name:
            NameFull: Amaravadi RK
      – PersonEntity:
          Name:
            NameFull: Vonderheide RH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 30
              M: 01
              Text: 2026 Jan 30
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2051-1426
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal for immunotherapy of cancer
              Type: main
ResultId 1